Document is current
Any future updates will be listed below
-
Authors
van der Horst, Hilma J. https://orcid.org/0000-0002-7997-1138
Csikós, Tamás
Quik, Marjolein
van der Schans, Jort J. https://orcid.org/0009-0007-5617-683X
de Lint, Klaas https://orcid.org/0000-0001-7134-444X
Nuñez Moreno, Gonzalo
Guan, Meijian
Karagoz, Kubra
Breij, Esther C. W. https://orcid.org/0000-0002-5368-6849
Santegoets, Kim C. M.
Chamuleau, Martine E. D. https://orcid.org/0000-0002-0123-9182
Roukens, M. Guy
Overdijk, Marije B.
Mutis, Tuna https://orcid.org/0000-0002-5557-7187
-
Funding
Funding for this research was provided by:
Genmab
- License Information
-
More Information
Article History
Received: 16 February 2025
Revised: 20 July 2025
Accepted: 27 August 2025
First Online: 6 October 2025
Competing interests
: GNM, MG, KK, MBO, KCMS, MGR, and ECWB are employees of Genmab and own Genmab warrants and/or stock. HJvdH, MBO, MEDC, ECWB, and TM are co-inventors on patents related to antibodies used in this study. MEDC consults for AbbVie, Novartis, and BYONDIS and has received research funding from AbbVie, BMS, Gilead, and Genmab. TM has received research support from Janssen Pharmaceuticals, Genmab, Takeda, Onkimmune, and Gilead.
